Tsai Chia-Jen, Kuo Yu-Hsuan, Wu Hung-Chang, Ho Chung-Han, Chen Yi-Chen, Yang Ching-Chieh
Department of Radiation Oncology, Chi Mei Medical Center, Tainan 71069, Taiwan.
Division of Hematology and Oncology, Department of Internal Medicine, Chi Mei Medical Center, Tainan 71069, Taiwan.
Cancers (Basel). 2021 Jul 26;13(15):3742. doi: 10.3390/cancers13153742.
We assessed the role of adjuvant radiotherapy on neck control and survival in patients with early oral cancer with solitary nodal involvement. We identified pT1-2N1 oral cancer patients with or without adjuvant radiotherapy from the 2007-2015 Taiwan Cancer Registry database. The effect of adjuvant radiotherapy on 5-year neck control, overall survival (OS) and disease-free survival (DFS) were calculated using the Kaplan-Meier method, log-rank tests, and Cox regression analysis. Of 701 patients identified, 505 (72.0%) received adjuvant radiotherapy and 196 (28.0%) had surgery alone. Patients receiving adjuvant radiotherapy were more likely to be aged <65 years, pT2 stage, poorly graded and without comorbid conditions (all, < 0.05). The 5-year OS and DFS differed significantly by receipt of adjuvant radiotherapy. Multivariable analysis showed adjuvant radiotherapy significantly associated with better 5-year OS (adjusted hazard ratio (aHR), 0.72; 95% confidence interval (CI), 0.54-0.97; = 0.0288) and DFS (aHR, 0.64; 95% CI, 0.48-0.84; = 0.0016). Stratified analysis indicated the greatest survival advantage for both 5-year OS and DFS in those with pT2 classification ( = 0.0097; 0.0009), and non-tongue disease ( = 0.0195; 0.0158). Moreover, adjuvant radiotherapy significantly protected against neck recurrence (aHR, 0.30; 95% CI, 0.18-0.51; < 0.0001). Thus, adjuvant radiotherapy is associated with improved neck control and survival in these early oral cancer patients.
我们评估了辅助放疗对伴有孤立性淋巴结转移的早期口腔癌患者颈部控制和生存的作用。我们从2007 - 2015年台湾癌症登记数据库中识别出接受或未接受辅助放疗的pT1 - 2N1口腔癌患者。使用Kaplan - Meier法、对数秩检验和Cox回归分析计算辅助放疗对5年颈部控制、总生存(OS)和无病生存(DFS)的影响。在识别出的701例患者中,505例(72.0%)接受了辅助放疗,196例(28.0%)仅接受了手术。接受辅助放疗的患者更可能年龄<65岁、处于pT2期、分级差且无合并症(所有P均<0.05)。5年OS和DFS因是否接受辅助放疗而有显著差异。多变量分析显示辅助放疗与更好的5年OS(调整后风险比(aHR),0.72;95%置信区间(CI),0.54 - 0.97;P = 0.0288)和DFS(aHR,0.64;95% CI,0.48 - 0.84;P = 0.0016)显著相关。分层分析表明,pT2分类患者(P = 0.0097;0.0009)和非舌部疾病患者(P = 0.0195;0.0158)在5年OS和DFS方面均具有最大的生存优势。此外,辅助放疗显著预防颈部复发(aHR,0.30;95% CI,0.18 - 0.51;P < 0.0001)。因此,辅助放疗与这些早期口腔癌患者颈部控制的改善和生存的提高相关。